PalmeaPharma strategic focus is to develop streamlined and effective inhibitors to a family of host enzymes playing a key role in a protein stability, intracellular trafficking, protein interactions and membrane association.

Discovery-stage proprietary small molecules are currently being developed for several indications in infectious diseases, inflammatory disorders, and anthrax intoxication.

PalmeaPharma combined forced with the lab of Prof. Gisou van der Goot (EPFL) to develop innovative and highly effective medical countermeasures against anthrax attacks. For more than 20 years, the van der Goot lab has generated foremost, extensive knowledge and know-how in the field of anthrax.

A family of host enzymes playing a key role in anthrax intoxication has been identified and discovery-stage proprietary small molecule inhibitors are currently being developed. Tested in a robust set of in vitro assays, prototype inhibitors have shown unprecedented efficacy to prevent cell intoxication.

PalmeaPharma aims at providing a rapid, safe, and high-quality therapeutic solution for stockpiling by national and international agencies.

.